ARS Pharmaceuticals, Inc. (SPRY) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

11/25

Growth 4 Margin 2 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

11
ARS Pharmaceuticals (SPRY) Q2 2026: 100% Market Share Growth Signals Shift to Provider-Focused Commercial Execution
August 18, 2026
10
ARS Pharmaceuticals (SPRY) Q1 2026: NEFI Prescription Volume Triples, Payer Access Set for July Inflection
May 15, 2026
10
ARS Pharmaceuticals (SPRY) Q4 2025: NEFI Penetrates 22,500 Prescribers as Refill Dynamics Set Up 2026 Growth
March 09, 2026
12
ARS Pharmaceuticals (SPRY) Q3 2025: NEFI U.S. Revenue Jumps 2.5x, DTC and Global Expansion Set Stage for 2026
November 10, 2025
12
ARS Pharmaceuticals (SPRY) Q2 2025: NEFI Scripts Jump 180% as DTC and Pediatric Launches Expand Reach
August 13, 2025
11
ARS Pharmaceuticals (SPRY) Q1 2025: NEFI Coverage Doubles to 57%, Tipping Point for Needle-Free Epinephrine
July 03, 2025
10
ARS Pharmaceuticals (SPRY) Q4 2024: $314M Cash Fuels Neffy Launch Acceleration and Coverage Expansion
March 20, 2025

Browse all companies